ENXTBR:UCBPharmaceuticals
UCB (ENXTBR:UCB) Posts New KYGEVVI Data, Is The Stock Still A Bargain?
UCB (ENXTBR:UCB) stock is in focus after new Brain Communications data on KYGEVVI for early onset TK2 deficiency highlighted improved survival and functional outcomes, along with acceptable tolerability in treated patients.
See our latest analysis for UCB.
The latest KYGEVVI data arrives as UCB shares trade at €255.0, with an 8.88% year to date share price return and a 51.64% total shareholder return over 1 year. This points to strong long term momentum alongside more modest recent gains.
If...